{
    "nctId": "NCT00940225",
    "briefTitle": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies",
    "officialTitle": "A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Tumors, Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 730,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below:\n\n  * Pancreatic Cancer\n  * Castration-Resistant Prostate Cancer (CRPC)\n  * Hepatocellular Carcinoma (HCC)\n  * Gastric or Gastroesophageal Junction Cancer\n  * Melanoma\n  * Small Cell Lung Cancer (SCLC)\n  * Ovarian cancer, primary peritoneal or fallopian tube carcinoma\n  * Breast cancer that is one of the following subtypes: estrogen receptor positive breast cancer, estrogen receptor/progesterone receptor/HER2-negative (triple-negative), or inflammatory (regardless of receptor status) disease histology\n  * Non-Small Cell Lung Cancer (NSCLC)\n* Certain requirements for prior therapies may apply\n* The subject has documented progressive disease at screening\n* Subjects having any tumor type of other than CRPC must have at least one lesion that is not within a previously irradiated field and is measurable on CT or MRI scan\n* The subject has recovered to baseline or CTCAE \u2264 Grade 1 from toxicities related to prior treatment (some exceptions apply)\n* The subject is \u2265 18 years old on the day of consent\n* Tissue samples from archival or fresh tissue, or a tissue block of the subject's tumor\n* The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* The subject has adequate organ function\n* The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document\n* Sexually active fertile subjects (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for 3 months after the last dose of the study drug(s)\n* Female subjects of childbearing potential must have a negative pregnancy test at screening\n\nExclusion Criteria:\n\n* The subject has experienced clinically-significant hematemesis or hemoptysis of \\>0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\n* The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or encasing a major blood vessel\n* Certain restrictions on prior treatments apply\n* The subject has known symptomatic or uncontrolled brain metastases or epidural disease\n* The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results that are above (1.3x)the laboratory upper limit of normal\n* The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and antiplatelet agents (low-dose aspirin (\u226481 mg/day), low-dose warfarin (\u22641mg/day, and prophylactic low molecular weight heparin (LMWH) are permitted)\n* The subject has a corrected QT interval(QTcF)\\>500 ms at screening\n* The subject has uncontrolled, significant intercurrent illness\n* The subject is unable to swallow capsules\n* The subject is pregnant or breastfeeding\n* The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation\n* The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee\n* The subject has had another diagnosis of malignancy requiring systemic treatment within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}